Literature DB >> 364545

Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species.

B J Whittle, S Moncada, J R Vane.   

Abstract

The activity of prostacyclin (PGI2), PGE1 or PGD2 as inhibitors of platelet aggregation in plasma from human, dog, rabbit, rat, sheep and horse was investigated. Prostacyclin was the most potent inhibitor in all species. PGD2 was a weak inhibitor in dog, rabbit and rat plasma whereas PGE1 and prostacyclin were highly active. Theophylline or dipyridamole potentiated the inhibition of human platelet aggregation by prostacyclin, PGE1 or PGD2. Compound N-0164 abolished the inhibition by PGD2 of human platelet aggregation but did not inhibit the effects of PGE1 or prostacyclin. The results suggest that prostacyclin and PGE1 act on similar sites on platelets which are distinct from those for PGD2.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 364545     DOI： 10.1016/0090-6980(78)90216-2

Source DB:  PubMed          Journal:  Prostaglandins        ISSN： 0090-6980


  53 in total

1.  Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans.

Authors:  Wen-Liang Song; Jane Stubbe; Emanuela Ricciotti; Naji Alamuddin; Salam Ibrahim; Irene Crichton; Maxwell Prempeh; John A Lawson; Robert L Wilensky; Lars Melholt Rasmussen; Ellen Puré; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

2.  Prostaglandins and the human mucosal alimentary cyclic AMP system.

Authors:  B Simon; H Kather
Journal:  Dig Dis Sci       Date:  1979-12       Impact factor: 3.199

3.  Post-translational modification regulates prostaglandin D2 synthase apoptotic activity: characterization by site-directed mutagenesis.

Authors:  Louis Ragolia; Christopher E Hall; Thomas Palaia
Journal:  Prostaglandins Other Lipid Mediat       Date:  2006-11-07       Impact factor: 3.072

4.  Prostacyclin receptor deletion aggravates hippocampal neuronal loss after bilateral common carotid artery occlusion in mouse.

Authors:  G Wei; K K Kibler; R C Koehler; T Maruyama; S Narumiya; S Doré
Journal:  Neuroscience       Date:  2008-08-20       Impact factor: 3.590

5.  Clinical and laboratory effects of nifedipine in Raynaud's phenomenon.

Authors:  S J Hawkins; C M Black; N D Hall; A McGregor; E F Ring; P J Maddison
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

6.  Changes of the activities of enzymes involved in prostaglandin synthesis in rat skin during development and aging.

Authors:  K Ikai; M Ujihara; Y Urade
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

7.  Dendritic cells express hematopoietic prostaglandin D synthase and function as a source of prostaglandin D2 in the skin.

Authors:  Chieko Shimura; Takahiro Satoh; Ken Igawa; Kosuke Aritake; Yoshihiro Urade; Masataka Nakamura; Hiroo Yokozeki
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

8.  Indomethacin inhibits eosinophil migration to prostaglandin D2 : therapeutic potential of CRTH2 desensitization for eosinophilic pustular folliculitis.

Authors:  Naoko Kataoka; Takahiro Satoh; Aiko Hirai; Kazumi Saeki; Hiroo Yokozeki
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

9.  Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.

Authors:  M F Martin; P M Dowd; E F Ring; E D Cooke; P A Dieppe; J D Kirby
Journal:  Ann Rheum Dis       Date:  1981-08       Impact factor: 19.103

10.  Effects of beraprost on the transmembrane potentials of guinea-pig ventricular muscles during normoxia and hypoxia-reoxygenation.

Authors:  Y Ueno; K Shigenobu; S Nishio
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.